<DOC>
	<DOCNO>NCT02587325</DOCNO>
	<brief_summary>mTOR activation show relevant development progression pulmonary hypertension . Inhibition mTOR show reverse regress pulmonary hypertension animal model . ABI-009 albumin-bound mTOR inhibitor improve penetration lung tissue .</brief_summary>
	<brief_title>ABI-009 , mTOR Inhibitor , Patients With Severe Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Male female age &gt; 18 year old current diagnosis WHO Group 1 PAH include idiopathic pulmonary arterial hypertension ( IPAH ) , heritable pulmonary arterial hypertension ( HPAH ) , drug toxin induce PAH , PAH associate connective tissue disease , congenital heart defect ( repair great 1 year prior Screening ) Must meet follow hemodynamic definition prior initiation study drug Mean PAP ≥ 25 mm Hg PCWP leave ventricular end diastolic pressure ( LVEDP ) ≤ 12 mm PVR &gt; 5 mmHg/L/min ( Woods unit ) Functional class III IV accord WHO set forth Dana Point Classification 2008 Meeting On 2 specific standard PAH therapy ( ≥ 12 consecutive week stable dose ≥ 8 consecutive week ) unless document inability tolerate 2 standard therapy Meet follow criterion determine pulmonary function test complete 24 week prior screen , perform without bronchodilation : Forced expiratory volume one second ( FEV1 ) ≥ 55 % predict normal FEV1 : force vital capacity ( FVC ) ratio ≥ 0.60 6MWD ≥150 meter ≤450 meter Negative serum pregnancy test Female childbearing age either surgically sterilize use acceptable method contraception Ability provide write informed consent patient legal guardian Exclusion criterion : History heart disease include leave ventricular ejection fraction ( LVEF ) ≤ 40 % clinically significant valvular constrictive atherosclerotic heart disease ( myocardial infarction , angina , cerebrovascular accident ) History malignancy 2 year prior enrollment Pulmonary hypertension ( PH ) belong group 2 5 2013 Nice classification Current recent ( &lt; 3 month ) use inotropic vasopressor agent treatment PAH Recent ( &lt; 3 month ) PAH related hospital admission History allergic reaction attribute compound similar chemical biologic composition include macrolide ( eg , azithromycin , clarithromycin , dirithromycin , erythromycin ) ketolide antibiotic Uncontrolled diabetes mellitus define HbA1c &gt; 8 % despite adequate therapy Uncontrolled hyperlipidemia ( serum triglyceride ≥300 mg/dL ) Serum cholesterol ≥350 mg/dL Surgery within 3 month start date study drug Baseline cytopenia : Absolute Neutrophil Count ≤ 1.5 x 109/L Hemoglobin ≤ 9 g/dL Platelet count &lt; 100,000/mm3 Baseline liver disease : ALT/AST , total bilirubin , alkaline phosphatase &gt; 1.5 x ULN Baseline renal disease : creatinine &gt; 1.5 ULN and/or creatinine clearance ( Cockroft formula ) ≤ 60 mL/min Inability attend schedule clinic visit Prior use study drug within previous 6 month enrollment Previous lung transplant Naïve available standard PAH therapy Concomitant genetic acquire immunosuppressive disease ( HIV , AIDS ) Uncontrolled intercurrent illness opinion investigator would limit compliance tolerance study requirement ( eg , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , diabetes , uncontrolled hypertension , coronary artery disease , psychiatric illness/social situation ) Concomitant enrollment another investigational treatment protocol PAH Use strong inhibitor inducer CYP3A4 within 14 day prior receive first dose ABI009 . Additionally , use know CYP3A4 substrates narrow therapeutic window ( fentanyl , alfentanil , astemizole , cisapride , dihydroergotamine , pimozide , quinidine , terfanide ) within 14 day prior receive first dose ABI009</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>